$IBRX · ImmunityBio, Inc.

ImmunityBio filed an 8-K on October 14, 2026, announcing FDA expansion of ANKTIVA's approved indication to include BCG-unresponsive NMIBC patients with papillary-only tumors. The prior April 2024 approval covered CIS with or without papillary tumors; this expansion adds papillary-only disease, which represents approximately 85% of the NMIBC patient population. ANKTIVA plus BCG is now the first FDA-approved therapy for both CIS and papillary-only BCG-unresponsive NMIBC.

Extended-hours trading shows IBRX at $10.00, up +0.91% from the regular-session close of $9.90, reflecting modestly positive initial reception to the label expansion. On a $10.50B market cap, the expanded addressable population covering ~85% of NMIBC patients represents a material commercial catalyst.

This label expansion roughly doubles ANKTIVA's addressable NMIBC market by adding papillary-only patients, establishing it as the sole FDA-approved therapy across the entire BCG-unresponsive NMIBC

This is the first FDA approval covering BCG-unresponsive NMIBC with papillary-only tumors, a historically underserved segment with limited nonsurgical options. ANKTIVA now holds a unique position as the only approved therapy spanning both CIS and papillary-only disease in this setting.

The prescribing information warns that delaying cystectomy can lead to metastatic bladder cancer, which can be lethal. If patients show high-grade disease after a second induction course, cystectomy must be reconsidered — a risk that could limit real-world adoption.